Sharemaestro Newsreel

Zimmer Biomet Deal Closes, Pacira Receives $73.6M Cash

Pacira BioSciences (NASDAQ:PCRX) Releases Quarterly Earnings Results, Beats Estimates By $0.08 EPS

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

Aurora Cannabis Q1 Preview: What to expect (ACB:NASDAQ)

Bridion, with $1.6B in U.S. sales, gets a generic drug

Dr. Reddy's Laboratories has launched its generic equivalent of Bridion® (Sugammadex Injection) in the United States, becoming the first-to-market on the day of generic availability. Bridion® had U.S. sales of approximately $1.6 billion for the 12-month period ending May 2026. This launch expands Dr. …

Earnings To Watch: United Therapeutics (UTHR) Reports Q2 Results Tomorrow

Hims & Hers Health (NYSE:HIMS) stock jumps 11% before earnings as margin ramp faces key test

Shareholder Alert: Ademi LLP investigates whether Lantheus Holdings, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating Lantheus Holdings, Inc. (NASDAQ: LNTH) following its recently announced transaction with Curium, questioning if the deal provides a fair price for public shareholders. Lantheus shareholders are set to receive $102.50 per share in cash, plus Contingent Value Rights potentially worth …

Evolus Number of Employees 2026 | Employee Count & Headcount Data

Evolus, Inc. (EOLS) had approximately 348 employees worldwide as of March 2026, marking a 50.4% growth since 2023 but a 4.0% decline year-over-year in 2026. The company is actively hiring, with 53 job postings in 2026, and its workforce is predominantly located in the …

RGC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Regencell Bioscience Holdings Ltd. Shareholders Have Opportunity to Lead Class Action Lawsuit!

Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Regencell Bioscience Holdings Ltd. (NASDAQ:RGC) and its officers. The lawsuit alleges that Regencell made materially false and misleading statements regarding its business, operations, and compliance policies between October 28, 2024, and October …

Supernus Pharmaceuticals (SUPN) Stock Rebounds As Revenue Growth Meets Profit Crunch

Eton will take emailed investor questions during Aug. 13 call

Eton Pharmaceuticals (NASDAQ: ETON) announced it will report its second-quarter 2026 financial results on Thursday, August 13, 2026. Management will host a conference call and live audio webcast at 4:30 p.m. ET (3:30 p.m. CT) to discuss the results and will accept investor questions …

HCM|HUTCHMED (China) Ltd|Price:11.550|Chg%:+0.420

This article provides a detailed overview of HUTCHMED (China) Ltd (HCM) stock performance, financial indicators, and analyst ratings. It highlights the company's current market trends, key figures, and an analyst consensus of "Buy" with a significant upside potential. The company's business segments in Oncology …

indivior plc. Positive Earnings Pre-Announcements

Indivior plc. (INDV.L, INDV) has pre-announced positive earnings, revising its fiscal year 2026 revenue guidance upwards from an estimated range of $1.215 - $1.285 Billion to $1.295 - $1.365 Billion. This announcement is part of a broader calendar of earnings pre-announcements available through RTTNews. …

Eton Pharmaceuticals to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026

Eton Pharmaceuticals has announced it will report its second-quarter 2026 financial results on Thursday, August 13, 2026. The company will also host a conference call and webcast to discuss these results and provide a business update.

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (Nasdaq: AKBA) reported granting options to purchase 61,000 shares of common stock to two new employees on July 31, 2026. These grants, made as an inducement for employment, comply with Nasdaq Listing Rule 5635(c)(4) and have an exercise price of $1.32 …

Top Biotech Gainers: UPC Cuts Loss, CPIX Gains Ahead Of Q2 Results, AUTL Builds Commercial Momentum

(RTTNews) - Today's top biotech gainers include Universe Pharmaceuticals, which recently filed its SEC report for the six months ended March 31, 2026; Cumberland Pharma, ahead of its second-quarter 2026 financial results due Tuesday; and Autolus Therapeutics, following the release of its preliminary quarterly …

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)

Monteverde & Associates PC, a class action firm, has announced an investigation into Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN) concerning its proposed sale to Indivior Pharmaceuticals, Inc. The firm is examining whether the deal, where Supernus shareholders would receive 1.5401 common shares of Indivior for …

Class Action Lawsuit Filed Against Hims & Hers Health, Inc. (HIMS)

A class action lawsuit has been filed against Hims & Hers Health, Inc. (HIMS), alleging securities fraud for making false statements regarding the deceptive promotion and sale of "knockoff" versions of Wegovy®. Shareholders who suffered losses between April 29, 2025, and June 23, 2025, …

Form 4 Alkermes plc. For: 3 August By Investing.com

This article announces that Alkermes plc (ALKS) filed a Form 4 on August 3rd. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) by company insiders (officers, directors, or beneficial owners of more than 10% …

Indivior and Supernus (SUPN) outline tax-free all-stock CNS merger of equals

Indivior Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc. announced a definitive agreement to merge in an all-stock, tax-free transaction, creating a U.S. biopharmaceutical company focused on central nervous system (CNS) diseases. The combined entity will be headquartered in Rockville, Maryland, with Supernus CEO Jack A. …

Akebia Therapeutics Inc expected to post a loss of 4 cents a share - Earnings Preview

Akebia Therapeutics Inc is anticipated to report a loss of 4 cents per share. This information comes from a Refinitiv earnings preview. The full article is available through a TradingView subscription.

BioXcel Shareholder Notice

Faruqi & Faruqi, LLP is investigating potential claims against BioXcel Therapeutics, Inc. (NASDAQ: BTAI) and encourages investors who lost over $100,000 to contact them before the September 5, 2023 deadline to seek lead plaintiff status. This investigation follows a significant stock drop after BioXcel …

Dear Teva Pharmaceutical Stock Fans, Mark Your Calendars for September 14

Teva Pharmaceutical Industries (TEVA) will replace its American Depository Shares with a direct listing of ordinary shares on the NYSE starting September 14, aiming to broaden its shareholder base and reduce capital costs. This strategic move could also lead to inclusion in major indices, …

Tilray Brands (NASDAQ:TLRY) Stock Price Up 2.2% Following Analyst Upgrade

Tilray Brands (NASDAQ:TLRY) saw its stock price increase by 2.2% after TD Securities upgraded the stock to a "strong-buy" rating. Despite the upgrade, analyst sentiment for Tilray remains mixed, with an average rating of "Moderate Buy" and a consensus price target of $11.00. The …

Emergent BioSolutions Inc expected to post earnings of 11 cents a share - Earnings Preview

Emergent BioSolutions Inc. (EBS) is expected to announce earnings of 11 cents per share. This information comes from a Refinitiv earnings preview. The full article is available through TradingView News, which offers access to Reuters and other news sources.

BioAge Labs posts partial recovery after deep selloff, rises 19% (BIOA:NASDAQ)

BioAge Labs (BIOA) saw its shares rise by 19% on Monday, marking a partial recovery after a significant 64% plunge on Friday. The initial selloff was attributed to Novo Nordisk's trial failure, which impacted BioAge Labs due to market concerns about similar drug mechanisms. …

Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We …

Supernus Pharmaceuticals Earnings: What To Look For From SUPN

Supernus Pharmaceuticals is set to report its Q2 earnings this Tuesday after market hours. Analysts expect the company's revenue to grow by 24.3% year-on-year, improving from the previous year's 5.6% increase. Despite Supernus Pharmaceuticals beating revenue expectations last quarter, it significantly missed EPS estimates, …

Alkermes (ALKS) insider David Gaffin details equity-award stock sales

Alkermes plc insider David Gaffin plans to sell Alkermes common stock through Merrill Lynch, with a total market value of $98,811.72. These sales relate to restricted stock unit and performance share unit awards that vested between 2014 and 2016. Gaffin has also reported monthly …

Alkermes plc (NASDAQ: ALKS) insider schedules 9,000-share sale after option exercise

An Alkermes plc insider, Craig Hopkinson, plans to sell 9,000 ordinary shares on August 3, 2026, valued at approximately $437,220. These shares originate from employee stock option exercises and vesting of performance and restricted stock awards. The filing also reveals Hopkinson's previous monthly sales …

Bausch Health Companies Stock: 5 Straight Green Days, Up 56%

Bausch Health Companies (BHC) stock has seen a significant surge, climbing 56% over five consecutive trading days and adding $923 million to its market value. While this streak shows strong near-term momentum and attention from the market, investors are encouraged to re-evaluate the underlying …

Two New Akebia Hires Get Stock Options With 4-Year Vesting

Akebia Therapeutics (Nasdaq: AKBA) granted stock options for an aggregate of 61,000 shares to two new employees on July 31, 2026. These inducement awards, granted under Nasdaq Listing Rule 5635(c)(4), have an exercise price of $1.32 per share and will vest over four years, …

Niagen Bioscience Selects Global Drug Development Pioneer Evotec to Advance Preclinical Development for NB4168

Niagen Bioscience has partnered with Evotec, a global drug discovery and development company, to advance the preclinical development of NB4168, their lead investigational candidate for rare pediatric diseases like Ataxia Telangiectasia (A-T). Evotec will conduct pharmacokinetic, pharmacodynamic, and bioanalytical studies to support Niagen Bioscience's …

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Lantheus Holdings, Inc. (NASDAQ: LNTH)

Monteverde & Associates PC, a class action law firm, has announced an investigation into Lantheus Holdings, Inc. (NASDAQ: LNTH) following its proposed sale to Curium US Holdings LLC. Shareholders are set to receive $102.50 per share in cash, plus potential contingent value rights of …

Organigram Global (TSX:OGI) Refreshes Cannabis Stocks Focus Across Markets

This article focuses on Organigram Global (TSX:OGI) and its position within the Canadian cannabis sector. It highlights a review that compares four leading companies—Organigram Global, SNDL, Village Farms International, and Auxly Cannabis Group—based on liquidity, operational discipline, capital allocation, and brand development. Organigram Global …